Judicial biomarker doctrine accountability

Introduction

Judicial Biomarker Doctrine Accountability refers to the proposed legal framework governing the use, interpretation, disclosure, and evidentiary reliability of biomarkers in judicial and regulatory decision-making. A biomarker is a measurable biological characteristic that can provide information about a physiological or pathological process, such as a blood marker, genetic characteristic, protein expression, imaging result, or molecular signature.

In legal proceedings, biomarkers may increasingly be used to establish disease, exposure to substances, treatment response, genetic predisposition, biological injury, or other scientifically relevant facts. The doctrine therefore asks an important question: how should courts ensure that biomarker evidence is scientifically reliable before allowing it to influence legal rights and liabilities?

There is currently no universally recognised independent “Judicial Biomarker Doctrine.” Its principles must be developed from evidence law, medical law, scientific-evidence standards, constitutional protections, privacy law, and judicial review principles.

Nature of biomarkers in judicial proceedings

Biomarkers can potentially serve several legal purposes. They may be introduced as evidence in:

• medical malpractice litigation;
• pharmaceutical liability cases;
• environmental contamination disputes;
• occupational-disease claims;
• criminal proceedings;
• discrimination cases;
• insurance disputes;
• regulatory proceedings;
• personal-injury litigation.

For example, a biomarker could be offered to establish that an individual was exposed to a chemical or that a particular biological injury occurred.

However, a biomarker does not necessarily prove the legal conclusion being asserted. A biological correlation must be distinguished from proof of legal causation.

Scientific validity

The first accountability requirement should be scientific validity.

A court should consider whether the biomarker has been scientifically validated for the specific purpose for which it is being introduced.

Relevant questions include:

1. Has the biomarker been independently validated?
2. What is its sensitivity and specificity?
3. Is there a recognised reference population?
4. Are false positives and false negatives known?
5. Has the testing method been reliably performed?
6. Has the scientific community evaluated the methodology?
7. Is the interpretation appropriate for the specific case?

A biomarker that is scientifically useful for medical diagnosis may not necessarily be sufficiently reliable for proving legal causation.

General scientific evidence standards

In the United States, Daubert v. Merrell Dow Pharmaceuticals, Inc. (1993) is a foundational case concerning expert scientific evidence.

The U.S. Supreme Court held that courts must act as gatekeepers concerning the admissibility of expert scientific testimony. Relevant considerations include whether the theory or technique can be tested, whether it has been subjected to peer review, its known or potential error rate, applicable standards, and general acceptance, although these factors are not rigid requirements.

Daubert provides a strong foundation for biomarker accountability because courts should examine the reliability of the scientific methodology rather than simply accepting a biological claim because it appears technologically sophisticated.

General Electric v. Joiner

In General Electric Co. v. Joiner (1997), the U.S. Supreme Court emphasised that courts may scrutinise the reasoning connecting scientific evidence to the conclusion offered.

This is particularly important for biomarkers.

A biomarker may reliably demonstrate a biological change without establishing that a particular defendant caused that change. Courts must therefore examine the analytical connection between the biomarker and the ultimate legal conclusion.

Kumho Tire v. Carmichael

Kumho Tire Co. v. Carmichael (1999) extended the principles governing expert testimony beyond traditional scientific evidence to technical and specialised expertise.

The decision reinforces the broader proposition that courts must assess the reliability of expert methodology when expert testimony is offered.

This could apply to medical experts interpreting complex biomarker data.

Biomarker evidence and causation

Causation is one of the most difficult issues.

Suppose a claimant demonstrates an elevated biological marker associated with exposure to a particular chemical. The evidence may establish exposure, but it does not necessarily prove that the defendant's conduct caused the claimant's disease.

The court may need to distinguish:

Exposure → biological response → clinical condition → legal injury → defendant's responsibility.

Each link requires appropriate evidence.

Biomarker evidence should therefore generally be considered alongside epidemiological, clinical, occupational, environmental, and factual evidence.

Pharmaceutical and medical liability

Biomarkers are increasingly used in drug development and personalised medicine. A pharmaceutical company may rely upon a biomarker to identify patients likely to respond to a treatment.

If a biomarker is incorrectly validated or interpreted, patients may suffer harm.

Legal accountability may arise through:

• product-liability claims;
• medical malpractice;
• regulatory enforcement;
• professional negligence;
• inadequate disclosure of limitations.

The precise liability depends on the jurisdiction and applicable legislation.

Genetic biomarkers and privacy

Genetic biomarkers present additional privacy concerns.

A genetic marker may reveal information about:

• disease susceptibility;
• ancestry;
• hereditary conditions;
• biological relationships;
• potential future health risks.

In S. and Marper v. United Kingdom (2008), the European Court of Human Rights recognised the privacy implications associated with retaining DNA information.

The case is relevant to judicial biomarker governance because biological information does not lose its privacy character merely because it is useful to law enforcement or judicial authorities.

Genetic discrimination

Biomarker evidence should also be subject to non-discrimination safeguards.

A biomarker showing genetic susceptibility to a disease should not automatically establish that a person is currently ill or incapable of performing a job.

The legal system must distinguish between:

• predisposition;
• actual disease;
• probability of future disease;
• functional impairment.

Failing to make these distinctions can produce discriminatory outcomes.

Biomarkers and criminal proceedings

Biomarkers may potentially be used in criminal investigations, but their evidentiary significance must be carefully limited.

A biological marker may indicate exposure to a substance or physiological condition, but it may not reliably establish:

• intent;
• knowledge;
• identity;
• responsibility;
• precise timing of an event.

Courts should therefore avoid treating scientific measurements as automatically determinative of legal guilt.

Chain of custody and laboratory accountability

Biomarker evidence also requires reliable handling.

A court should consider whether:

• the sample was properly collected;
• contamination was prevented;
• storage conditions were appropriate;
• laboratory procedures were validated;
• instruments were calibrated;
• the chain of custody was documented;
• testing personnel were appropriately qualified.

A scientifically valid biomarker can still become unreliable evidence if the sample or testing process was compromised.

Judicial transparency

Courts should provide adequate reasoning when accepting or rejecting biomarker evidence.

Judicial accountability requires explaining:

• what scientific evidence was relied upon;
• what limitations were recognised;
• why the expert methodology was considered reliable;
• how competing scientific evidence was evaluated.

This is especially important when biomarker evidence has significant consequences for liberty, employment, medical treatment, or financial liability.

Precaution and uncertainty

Biomarker science frequently involves uncertainty.

A court should not automatically treat uncertainty as proof that the evidence is useless. Nor should uncertainty be ignored merely because the technology appears advanced.

A proportional approach is preferable:

• strong validation → greater evidentiary weight;
• limited validation → cautious or restricted use;
• significant methodological uncertainty → possible exclusion or very limited weight.

Regulatory biomarker decisions

Biomarkers may also influence regulatory decisions concerning drugs and medical products.

Regulators may use biomarkers as surrogate endpoints in clinical trials. However, a biomarker that predicts a biological effect does not necessarily establish that a treatment improves long-term clinical outcomes.

Regulatory authorities therefore need procedures for validating surrogate endpoints and monitoring whether biomarker-based approvals produce the expected clinical benefits.

Accountability of experts

Experts interpreting biomarker evidence should have professional responsibilities concerning accuracy and disclosure.

They should disclose:

• methodological limitations;
• error rates;
• alternative interpretations;
• conflicts of interest;
• relevant contrary evidence.

An expert should not present a probabilistic biomarker association as an absolute biological fact.

Conclusion

Judicial Biomarker Doctrine Accountability is currently a developing conceptual framework rather than an established independent doctrine of law. Its foundations lie in scientific-evidence law, medical jurisprudence, privacy law, expert-witness standards, and judicial-review principles.

The central principle should be:

A biomarker may provide scientifically relevant evidence, but its legal significance depends upon the reliability of the testing method, the validity of the scientific inference, and the connection between the biological finding and the legal issue before the court.

The cases Daubert v. Merrell Dow, General Electric v. Joiner, Kumho Tire v. Carmichael, and S. and Marper v. United Kingdom provide important foundations for evaluating scientific reliability, expert methodology, and biological privacy.

Accordingly, courts should treat biomarker evidence as specialised scientific evidence requiring methodological scrutiny, rather than assuming that technologically sophisticated biological measurements are automatically accurate, conclusive, or legally determinative.